Clareo Health | An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
Male or female, age equal to or above 18 years at the time of signing the informed consent.
Patients diagnosed with diabetes mellitus.
Patients scheduled to start treatment with Fiasp® based on the clinical judgement of their treating physician.
You may not be if
Known or suspected hypersensitivity to study product(s) or related products.
Patients on or likely to use insulin pump therapy during the study period
Previous participation in this study. Participation is defined as having given signed informed consent.
Mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation.
Participation in any clinical study of an approved or non-approved investigational medicinal product within 1 month before treatment start.
Any disorder which in the opinion of the treating physician may jeopardise the patient's safety or compliance with the protocol.
